GET THE APP

DMAP Catalysed Selective Synthesis of Thiopyrano[2,3-B]Quinoline Derivatives through Cascade Protocol

Der Pharma Chemica
Journal for Medicinal Chemistry, Pharmaceutical Chemistry, Pharmaceutical Sciences and Computational Chemistry

ISSN: 0975-413X

ilbet

süperbetin giriş

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission Systemof respective journal.

agariookey oyna istanbul okey

Research Article - Der Pharma Chemica ( 2021) Volume 13, Issue 8

DMAP Catalysed Selective Synthesis of Thiopyrano[2,3-B]Quinoline Derivatives through Cascade Protocol

Sreenivas Avula* and Srikanth Reddy Narra
 
Fluoroorganics Division, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, Telangana-500607, India
 
*Corresponding Author:
Sreenivas Avula, Fluoroorganics Division, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, Telangana-500607, India, Tel: +91-9346676343, Email: [email protected]

Received Date: Aug 01, 2021 / Accepted Date: Aug 17, 2021 / Published Date: Aug 31, 2021

Abstract

A convenient and rapid synthesis of hitherto unknown Thiopyrano[2,3-b]quinoline derivatives (3) from β-aroyl-thioacetanilides (1) and 2-chloro quinoline-3-carbaldehyde (2) in the presence of simple organic bases. Initially, β-aroyl-thioacetanilides undergo condensation with 2-chloro quinoline-3-carbaldehyde (2) and followed by intramolecular cyclization (SNAr) to obtained the Thiopyrano[2,3-b]quinoline derivatives (3a-3o). For this transformation, we have found that DMAP is the best catalyst for chemo-selective synthesis of Thiopyrano[2,3-b]quinolones derivatives in high yields. All the final compounds were well characterized by 1H NMR, 13C NMR and HRMS, further confirmed by single X-ray crystallography for 3a and 4a compounds.

Keywords

Thiopyrano [2,3-b]quinoline, β-aroyl-thioacetanilides, 2-chloro quinoline-3-carbaldehyde.

Introduction

Construction of new heterocyclic ring systems by using new synthetic techniques is very important in synthetic and medicinal chemistry. From the past several decades quinoline derivatives received the great attention in medicinal chemistry as an active pharmacophores [1] and the fused quinoline derivatives also have the good biological profile such as antibacterial [2,3] antimalarial [4-8] antifungal [9] anti-inflammatory [10] antihypertensive [11] antiproliferative [12] and anticancer [13] agents. The thiopyran fused quinoline framework which have structural similarities with MT477 (potential anticancer drug with a high activity against protein kinase C (PKC) isoforms [14] also possess a remarkable biological activities such as antagonistic activity [15-17] and antioxidant [18] agents. Some representative examples are outlined in Figure 1. In view of the importance of thiopyrano [2,3-b]quinoline it is necessary to develop an efficient method for the construction of this heterocyclic skeleton containing analogues.

Derpharma-chemica-biological

Figure 1. Some biological important 2H-thiopyrano[2,3-b]quinolones.

There are few reports available in literature on the synthesis of thiopyrano [2,3-b] quinoline derivatives. In 2009,wang and co-workers [19] reported the synthesis of thiopyran fused quinoline derivatives starting from aromatic aldehydes, naphthalen-2- amine and tetrahydrothiopyran-4-one in the presences of I2 (Figure 2a). After that, Singh and co-workers [20] pioneered the synthesis of fused thiopyranquinolone from 2-thione analogs of 3-formylquinolines and acrylonitrile (via Domino Michael addition followed by cyclization reaction) in the presences of triethylamine (Figure 2b). In 2014, Patel and co-workers [21] synthesized 4H-substituted thiopyrano [2,3-b]quinolines derivatives from 2-mercaptoquinoline-3-carbaldehyde, malononitrile and thiol-based nucleophiles in the presences of L-Proline (Figure 2c). However to the best of our knowledge DMAP annulation reaction of β -ketothioamides and 2-chloroquinoline-3-carbaldehydes has not reported before, In continuation of our efforts on synthesis of novel heterocyclic compounds, by utilizing β-aroyl-thioacetanilides [22-25] we report here the synthesis of novel thiopyrano [2, 3-b] quinoline (3) derivatives from 2-chloro quinoline-3-carbaldehyde in very good yields using DMAP as a catalyst.

Derpharma-chemica-approaches

Figure 2. Previous approaches Vs. current approach for Synthesis of Thiopyranoquinolines.

Materials and Methods

General

Melting points were recorded on a Veego programmable melting point apparatus and are uncorrected. IR spectra were recorded on a PerkineElmer FT-IR 240-Cspectrophotometer using KBr optics. 1H NMR spectra were recorded on Bruker AV 300 MHz in CDCl3 using TMS as internal standard. Electron Spray Ionization (ESI) and high-resolution mass spectra were recorded on QSTARXL hybrid MS/MS system (Applied Biosystems, USA). All the reactions were monitored by thin layer chromatography (TLC) on pre-coated silica gel 60F254 (mesh); spots were visualized under UV light. The crystallographic data can be obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html or from the Cambridge Crystallographic Data Centre (CCDC), 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44(0) 1223 336 033; email: [email protected]

General method for Synthesis of the thiopyrano[2,3-b]quinoline derivatives (3a-3o)

An equimolar mixture of 3-(4-ethylphenyl)-3-oxo-N-phenylpropane thioamide 1a (283 mg, 1.0 mmol)) and 2-chloro-6-methoxy quinoline-3- carbaldehyde 2b (221 mg, 1.0 mmol)) was stirred under refluxed in ethanol (15mL) containing DMAP (N,N-dimethy,4- amino pyridine) (12.2mg, 0.1mmol) for 4 h. After completion of the reaction (monitored by TLC), the reaction mixture was allowed to room temperature, and ethanol was evaporated under reduced pressure then the reaction mixture was diluted with water (15mL) and extracted with ethyl acetate (2*15mL), the combined organic layers were washed with brine (2*15mL) dried over Na2SO4 , filtered and concentrated in vacuo. The crude was purified by column chromatography to afford (Z)-(4-Ethyl phenyl)(2-(phenylimino)-2H-thiopyrano[2,3-b] quinolin-3-yl)methanone (3a) (378.9 mg, 90%). Similar procedure is adopted to prepare remaining compounds (3a-3o).

(Z)-(4-Ethylphenyl)(2-(phenylimino)-2H-thiopyrano [2,3-b]quinolin-3-yl)methanone (3a)

Yellow solid; Yield: 90%; Rf (30% EtOAc/hexane) 0.50; mp < 250oC1H NMR (300 MHz, CDCl3) δ 1.26 (t, J = 7.5 Hz, 3H), 2.76-2.69 (q, J = 7.5 Hz, 2H), 6.84 (d, J = 7.5 Hz, 2H), 7.11 (t, J = 7.5 Hz, 1H), 7.33 (t, J = 8.3 Hz, 4H), 7.43 (s, 1H), 7.53 (t, J = 7.5 Hz, 1H), 7.74 (t, J = 7.5 Hz, 1H) 7.82 (d, J = 8.3 Hz, 1H), 7.92 (d, J = 8.3 Hz, 1H), 7.96 (d, J = 8.3 Hz, 2H), 8.14 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 15.0, 29.6, 119.0, 122.0, 125.1, 126.3, 126.9, 128.0, 129.3, 129.9, 131.8, 134.0, 134.3, 137.6, 147.7, 149.2, 150.7, 155.6, 194.2; ; IR (KBr) υmax 2967, 1669, 1552, 1563, 1259, 695 cm-1; ESI-MS421 [M+H]+; HRMS (ESI) calcd for C27H20N2OS [M+H]+ 421.13691, found 421.13537. (Figures 3,4)

Derpharma-chemica-methanone

Figure 3. 1H NMR of (Z)-(4-Ethylphenyl)(2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3a).

Derpharma-chemica-phenylimino

Figure 4. 13C NMR of (Z)-(4-Ethylphenyl)(2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3a).

(Z)-(4-Methoxyphenyl)(2-(phenylimino)-2H-thiopyrano [2,3-b]quinolin-3-yl)methanone (3b)

Yellow solid; Yield: 88%; Rf (30% EtOAc/hexane) 0.48; m.p. 191-192oC; 1H NMR (300 MHz, CDCl3) δ 3.88 (s, 3H), 6.85 (d, J = 7.5 Hz, 2H), 6.97 (d, J = 8.8, Hz, 2H), 7.11 (t, J = 7.5 Hz, 1H), 7.33 (t, J = 7.7 Hz, 2H), 7.4(s, 1H), 7.53 (t, J = 7.7 Hz, 1H), 7.74 (t, J = 8.3 Hz, 1H), 7.82 (d, J = 7.9 Hz, 1H), 7.92 (d J = 8.3 Hz, 1H), 8.04 (d, J = 8.8 Hz, 2H),8.14(s, 1H);13C NMR (75 MHz, CDCl3) δ55.5. 113.8, 119.0, 121.9, 125.2,126.7, 126.9,128.1, 128.5, 129.2, 129.3, 129.5, 131.7, 132.1, 133.5, 134.1, 134.6, 137.5,137.7, 147.6, 149.2, 155.5, 155.7, 163.9, 193.1; IR (KBr) υmax 1662, 1587, 1568, 1552, 1253, 758, 701 cm-1; ESI-MS 423 [M+H]+; HRMS (ESI) calcd for C26H18O2N2S [M+H]+423.11618, found 423.11645. (Figure 5,6)

Derpharma-chemica-Methoxyphenyl

Figure 5. 1H NMR of (Z)-(4-Methoxyphenyl)(2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone(3b).

Derpharma-chemica-quinolin

Figure 6. 13C NMR of (Z)-(4-Methoxyphenyl)(2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone(3b).

(Z)-Phenyl(2-(phenylimino)-2H-thiopyrano[2,3-b] quinolin-3-yl)methanone (3c)

Yellow solid; Yield: 82%; Rf (30% EtOAc/hexane) 0.49;m.p. 190-191oC; 1H NMR (300 MHz, CDCl3) δ 6.82 (d, J = 8.3 Hz, 2H), 7.11 (t, J =7.5 Hz, 1H), 7.32 (t, J = 7.9 Hz, 2H), 7.47 (s, 1H), 7.51 (d, J = 7.5 Hz, 2H), 7.57 (t, J = 7.5 Hz, 2H), 7.75 (t, J = 8.6 Hz, 1H), 7.83 (d, J = 7.9 Hz, 1H), 7.93 (d, J = 8.6 Hz, 1H), 8.05 (d, J = 7.1Hz, 2H), 8.16 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 119.0, 121.9, 125.1, 126.3, 126.9, 128.2, 128.5, 129.3, 129.5, 131.9, 133.5, 134.6, 136.5, 137.5, 137.7, 147.7, 149.1, 155.6, 194.6; IR (KBr) υmax 2925, 1668, 1557, 1263, 719, 698 cm-1; ESI-MS 393 [M+H]+; HRMS (ESI) calcd for C25H16ON2S [M+H]+393.10561, found 393.10574. (Figures 7,8)

Derpharma-chemica-phenylimino

Figure 7. H NMR of (Z)-Phenyl(2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3c).

Derpharma-chemica-Phenyl

Figure 8. 13C NMR of (Z)-Phenyl(2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3c).

(Z)-(4-Fluorophenyl)(2-(phenylimino)-2H-thiopyrano [2,3-b]quinolin-3-yl)methanone (3d)

Yellow solid; Yield: 81%; Rf (30% EtOAc/hexane) 0.48; m.p. 166-167°C; 1H NMR (300 MHz, CDCl3) δ 6.82 (d, J = 7.3 Hz, 2H), 7.19-7.09 (m, 3H), 7.33 (t, J = 7.9Hz, 2H), 7.46 (s, 1H), 7.54 (t, J = 7.9 Hz, 1H), 7.76 (t, J = 8.3 Hz, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.93 (d, J = 8.3 Hz, 1H), 8.09-8.05 (q, 2H), 8.16 (s, 1H); 13C NMR (75MHz, CDCl3) δ 115.8 (d, J = 21.79 Hz), 119.0, 121.8, 125.4, 126.3, 127.2, 127.8, 128.3, 129.4, 132.2 (d, J = 6.35 Hz), 132.7 (d, J = 2.72 Hz), 135.0, 136.9, 138.2, 147.4, 148.6, 155.4, 155.6, 165.9 (d, J = 256.12 Hz), 193.1; IR (KBr) υmax 1667, 1595, 1548, 1257, 754 cm-1; ESI-MS 411 [M+H]+; HRMS (ESI) calcd for C25H15ON2FS [M+H]+411.09619, found 411.09588.(Figure 9 and 10)

Derpharma-chemica-quinolin

Figure 9. 1H NMR of (Z)-(4-Fluorophenyl)(2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3d).

Derpharma-chemica-Fluorophenyl

Figure 10. 13C NMR of Z)-(4-Fluorophenyl)(2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3d).

(Z)-(4-Chlorophenyl)(2-(phenylimino)-2H-thiopyrano [2,3-b]quinolin-3-yl)methanone (3e)

Yellow solid; Yield: 83%; Rf (30% EtOAc/hexane) 0.49; m.p. 202-203oC; 1H NMR (300 MHz, CDCl3) δ 6.81 (d, J = 7.5 Hz, 2H), 7.12 (t, J = 7.7 Hz, 1H), 7.33 (t, J = 7.7 Hz, 2H), 7.46 (d, J = 8.8 Hz, 3H), 7.54 (t, J = 7.7 Hz, 1H) ), 7.75 (t, J = 8.1, Hz, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.97 (d, J = 8.4 Hz, 2H), 8.16 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 118.9, 121.8, 125.2, 126.2, 127.0, 128.2, 128.8, 129.4, 130.8, 132.0, 134.7, 135.0, 137.0, 137.7, 139.9, 147.7, 148.9, 155.4, 193.5; IR (KBr) υmax 3052, 1665, 1588, 1544, 1256, 1083, 756 cm-1; ESI-MS 427 [M+H]+; HRMS (ESI) calcd for C25H15ON2ClS [M+H]+427.06664, found 427.06607. (Figure 11and 12)

Derpharma-chemica-phenylimino

Figure 11. 1H NMR of (Z)-(4-Chlorophenyl)(2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3e).

Derpharma-chemica-Chlorophenyl

Figure 12. 13C NMR of (Z)-(4-Chlorophenyl)(2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3yl)methanone (3e).

(Z)-(2-fluorophenyl)(2-(phenylimino)-2H-thiopyrano [2,3-b]quinolin-3-yl)methanone (3f)

Yellow solid; Yield: 88%; Rf (30% EtOAc/hexane) 0.48;m.p. 152-153oC; 1H NMR (300 MHz, CDCl3) δ 6.78 (d, J = 8.3 Hz, 2H), 7.13 – 7.08 (m, 2H), 7.27 (s, 1H), 7.32 (t, J= 8.3 Hz, 2H), 7.53 (t, J= 7.0 Hz, 2H), 7.59 (s, 1H), 7.74 (t, J= 8.3 Hz,1H), 7.82 (d, J= 7.6 Hz, 1H), 7.91 (d, J= 9.0 Hz, 1H), 7.99 (t, J= 7.6 Hz, 1H), 8.19 (s 1H); 13C NMR (75 MHz, CDCl3) δ 116.04 (d, J= 23.61 Hz), 118.9, 122.1, 124.53 (d, J= 2.72 Hz), 125.0, 126.13 (d, J= 10.89 Hz), 126.3, 126.9, 128.20 (d, J= 16.34 Hz), 129.4, 130.8, 131.9, 134.78 (d, J= 9.08 Hz), 135.2, 138.3, 138.6, 147.7, 149.1, 155.4, 155.9, 161.45 (d, J= 255.2 Hz), 190.7; IR (KBr) υmax 2925, 1655, 1610, 1586, 1556, 1286, 753 cm-1; ESI-MS 411 [M+H]+; HRMS (ESI) calcd for C25H15ON2FS [M+H]+411.09619, found 411.09595. (Figure 13 and 14)

Derpharma-chemica-phenylimino

Figure 13. 1H NMR (Z)-(2-fluorophenyl)(2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3f).

Derpharma-chemica-thiopyrano

Figure 14.13C NMR (Z)-(2-fluorophenyl)(2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3f).

(Z)-(7-Methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b] quinolin-3-yl)(phenyl)methanone (3g)

Yellow solid; Yield: 90%; Rf (30% EtOAc/hexane) 0.50;m.p. 167-168 oC; 1H NMR (300 MHz, CDCl3) δ 3.94 (s, 3H), 6.81 (d, J = 8.2 Hz, 2H), 7.07 (d, J = 3.2 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 7.32 (t, J = 8.2 Hz, 2H),7.41-7.39 (q, 1H), 7.45 (d, J = 4.5 Hz, 1H), 7.49 (t, J = 7.4 Hz, 2H), 7.62-7.53 (m, 2H), 7.83 (d, J = 9.3 Hz, 1H), 8.05 (t, J = 3.2 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 55.6, 104.1, 105.2, 119.0, 122.0, 124.8, 125.0, 125.7, 127.4, 128.4, 128.6, 128.9, 129.0, 129.3, 129.5, 129.6, 133.4, 134.6, 135.2, 136.4, 149.2, 158.0, 194.8; IR (KBr) υmax 3423, 3057, 2926, 1666, 1619, 1552, 1221 cm-1; ESI-MS 423 [M+H]+; HRMS (ESI) calcd for C26H18O2N2S [M+H]+423.11618, found 423.11556. (Figure 15and16)

Derpharma-chemica-Methoxy

Figure 15. 1H NMR of (Z)-(7-Methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)(phenyl)methanone (3g).

Derpharma-chemica-phenylimino

Figure 16. 13C NMR of (Z)-(7-Methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)(phenyl)methanone (3g).

(Z)-(4-Fluorophenyl)(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3h)

Yellow solid; Yield: 89%; Rf (30% EtOAc/hexane) 0.48; m.p. 179-180 oC; 1H NMR (300 MHz, CDCl3) δ 3.94 (s, 3H), 6.81 (d, J = 7.3 Hz, 1H), 7.07 (d, J = 2.7 Hz, 1H), 7.11 (t, J = 7.3 Hz, 2H), 7.16 (t, J = 8.5 Hz, 2H), 7.34 - 7.29 (m, 2H), 7.42 - 7.39 (m, 1H), 7.45 (s, 1H), 7.69 - 7.60 (m, 1H), 7.83 (d, J = 9.1 Hz, 1H), 8.09 -8.06 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 55.6, 105.2, 115.72 (d, J = 21.79 Hz), 118.9, 121.9, 124.9,125.1, 125.8, 126.3, 127.3, 128.4, 128.8, 129.4, 129.62 (d, J = 8.17 Hz), 132.20 (d, J = 9.99 Hz), 132.8, 134.8, 135.3, 136.5, 137.2, 140.3, 141.1, 149.1, 152.4, 155.9, 158.0, 165.92 (d, J = 255.21 Hz), 193.27; IR (KBr) υmax 3055, 2928, 1665, 1621, 1596, 1552, 1224, 694 cm-1; ESI-MS 441[M+H]+; HRMS (ESI) calcd for C26H17O2FN2S [M+H]+ 441.10675,found441.10592. (Figure 17 and 18)

Derpharma-chemica-Fluorophenyl

Figure 17. 1H NMR of (Z)-(4-Fluorophenyl)(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3b]quinolin-3-yl)methanone (3h).

Derpharma-chemica-thiopyrano

Figure 18. 13C NMR of (Z)-(4-Fluorophenyl)(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3b]quinolin-3-yl)methanone (3h).

(Z)-Benzo[d][1,3]dioxol-5-yl(7-methoxy-2-(phenylimino) -2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3i)

Yellow solid; Yield: 81%; Rf (30% EtOAc/hexane) 0.46; m.p. 181-182oC 1H NMR (300 MHz, CDCl3) δ 3.92 ( s, 3H), 6.05 (s, 2H), 6.85 (d, J = 7.4 Hz, 2H), 6.87 (d, J = 8.2 Hz, 1H), 7.05 (d, J = 2.2 Hz, 1H), 7.11 (t, J = 7.4 Hz, 1H),7.33 (t, J = 7.9 Hz, 2H), 7.40-7.32 (m, 2H), 7.53 (s, 1H), 7.64 (d, J = 8.2 Hz, 1H), 7.81( d, J=9.1 Hz,1H), 8.01(s, 1H); 13C NMR (75 MHz, CDCl3) δ 55.6, 101.9, 105.1, 107.9, 108.8, 119.0, 122.0, 124.7, 125.0, 126.8, 127.3, 129.3, 129.5, 131.1, 134.2, 136.2, 137.5, 144.0, 148.2, 149.3, 152.2, 152.4, 156.0, 157.9, 192.8; ; IR (KBr) υmax 2912, 1658, 1622, 1558, 1490, 1440, 1259, 1215, 1034 cm-1; ESI-MS 467 [M+H]+; HRMS (ESI) calcd for C27H18N2O4S [M+H]+ 467.51100, found 467.51110.(Figure 19,20)

Derpharma-chemica-dioxol

Figure 19. 1H NMR of (Z)-Benzo[d][1,3]dioxol-5-yl(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3i).

Derpharma-chemica-Benzo

Figure 20. 13C NMR of (Z)-Benzo[d][1,3]dioxol-5-yl(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3i).

(Z)-(4-ethylphenyl)(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3j)

Yellow solid; Yield: 87%; Rf (30% EtOAc/hexane) 0.52; m.p. 182-183 oC; 1H NMR (300 MHz, CDCl3) δ 1.26 (t, J = 7.6 Hz, 3H ), 2.74 –2.70 (q, 2H), 3.93 (s, 3H), 6.83 (d, J = 7.3 Hz, 2H), 7.05 (d, J = 2.7 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 7.34 - 7.29 (m, 4H), 7.40 – 7.38 (m, 2H), 7.82 (d, J = 9.3 Hz, 1H), 7.98 (d, J = 8.4 Hz, 2H), 8.02 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 15.0, 29.0, 55.6, 105.2, 119.0, 122.1, 124.7, 125.0, 127.4, 128.0, 128.9, 129.3, 129.6, 129.9, 133.9, 134.3, 136.2, 137.8, 144.0, 149.3, 150.7, 152.5, 156.0, 158.0, 194.3; IR (KBr) υmax 2915, 1629, 1615, 1530, 1218, 1020 cm-1; ESI-MS 451 [M+H]+; HRMS (ESI) calcd for C28H22N2O2S [M+H]+ 451.14655, found 451.14655. (Figure 21 and 22)

Derpharma-chemica-ethylphenyl

Figure 21. 1H NMR of (Z)-(4-ethylphenyl)(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3j).

Derpharma-chemica-methanone

Figure 22. 13C NMR of (Z)-(4-ethylphenyl)(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3j).

(Z)-(7-methoxy-2-((4-methoxyphenyl)imino)-2H-thiopyrano[2,3-b]quinolin-3-yl) (phenyl)methanone (3k)

Yellow solid; Yield: 79%; Rf (30% EtOAc/hexane) 0.50; m.p. 191-192 oC; 1H NMR (300 MHz, CDCl3) δ 3.78 (s, 3H), 3.93 (s, 3H), 6.87 – 6.80 (m, 4H), 7.06 (d, J = 2.6 Hz, 1H), 7.40 - 7.38 (m, 2H), 7.48 (t, J = 7.5 Hz, 2H), 7.58 (t, J = 7.5 Hz, 1H), 7.83 (d, J = 9.2 Hz, 1H), 7.04 (d, J = 8.5 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 55.4, 55.6, 105.2, 114.4, 120.9, 124.8, 128.5, 129.6, 133.4, 134.1, 136.2, 136.4, 137.9, 142.2, 154.9, 158.0, 195.4; IR (KBr) υmax 3414, 2928, 1674, 1626, 1546, 1493, 1218, 1163 cm-1; ESI-MS 453 [M+H]+; HRMS (ESI) calcd for C27H20N2O3S [M+H]+ 453.12674, found 453.12556. (Figure 23,24)

Derpharma-chemica-thiopyrano

Figure 23. 1H NMR of (Z)-(7-methoxy-2-((4-methoxyphenyl)imino)-2H-thiopyrano[2,3-b]quinolin-3-yl)(phenyl)methanone (3k).

Derpharma-chemica-imino

Figure 24. 13C NMR of (Z)-(7-methoxy-2-((4-methoxyphenyl)imino)-2H-thiopyrano[2,3-b]quinolin-3-yl)(phenyl)methanone (3k).

(Z)-(2-chlorophenyl)(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl) methanone (3l)

Yellow solid; Yield: 88%; Rf (30% EtOAc/hexane) 0.51; m.p. 176-177 oC; 1H NMR (300 MHz, CDCl3) δ 3.94 (s, 3H), 6.71 (d, J = 7.4 Hz, 1H), 7.12 - 7.07 (m, 2H), 7.29 (t, J = 7.7 Hz, 2H), 7.40 – 7.31 (m, 6H), 7.76 (d, J = 8.3 Hz, 1H), 7.80 (d, J = 9.4 Hz, 1H), 8.129 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 55.6, 105.3, 118.8, 125.0, 126.9, 129.3, 129.5, 130.0, 130.5, 130.9, 132.2, 136.0, 137.1, 137.4, 137.6, 137.9, 144.2, 149.1, 153.2, 154.9, 157.9, 160.0, 193.5; IR (KBr) υmax 2930, 1652, 1625, 1520, 1215, 1034, 742 cm-1; ESI-MS 457 [M+H]+; HRMS (ESI) calcd for C26H17N2O2ClS [M+H]+ 457.06993, found 457.06988. (Figure 25 and 26)

Derpharma-chemica-phenylimino

Figure 25. 1H NMR of (Z)-(2-chlorophenyl)(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3l).

Derpharma-chemica-methanone

Figure 26. 13C NMR of (Z)-(2-chlorophenyl)(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3l).

(Z)-(2-fluorophenyl)(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3m)

Yellow solid; Yield: 84%; Rf (30% EtOAc/hexane) 0.48; m.p. 185-186 oC; 1H NMR (300 MHz, CDCl3) δ 3.94 (s, 3H), 7.05 – 7.01 (m, 1H), 7.12 (d, J = 2.6 Hz, 1H), 7.28 (t, J = 7.7 Hz, 3H), 7.39 - 7.36 (m, 1H), 7.52 (t, J = 7.4 Hz, 2H), 7.60 (t, J = 7.7 Hz, 2H), 7.67 (d, J = 9.3 Hz, 1H), 7.78 (s, 1H), 8.09 (t, J = 7.7 Hz, 1H), 8.40 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 55.6, 105.3, 118.8, 124.8, 125.0, 126.9, 129.3, 129.5, 130.0, 130.5, 130.9, 131.7, 131.9, 132.33 (d, J = 27.10 Hz), 137.27 (d, J = 30.1 Hz), 137.6, 137.9, 144.2, 149.1, 156.4 (d, J = 255.26 Hz), 193.5; IR (KBr) υmax 3414, 2925, 1651, 1607, 1222 cm-1; ESI-MS 441 [M+H]+; HRMS (ESI) calcd for C26H17N2O2SF [M+H]+ 441.11933, found 441.10743. (Figure 27 and 28)

Derpharma-chemica-fluorophenyl

Figure 27.1H NMR of (Z)-(2-fluorophenyl)(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3m).

Derpharma-chemica-thiopyrano

Figure 28. 13CNMR of (Z)-(2-fluorophenyl)(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)methanone (3m).

(Z)-(2-((2,4-dichlorophenyl)imino)-7-methoxy-2H-thiopyrano[2,3-b]quinolin-3-yl)(phenyl)methanone (3n)

Yellow solid; Yield: 75%; Rf (30% EtOAc/hexane) 0.49; m.p. 179-180 oC; 1H NMR (300 MHz, CDCl3) δ 3.95 (s, 3H), 6.82 (d, J = 8.4 Hz, 1H), 7.16 (d, J = 3.0 Hz, 1H), 7.55 - 7.39 (m, 6H), 7.65 – 7.60 (m, 2H), 7.82 (d, J = 9.2 Hz, 1H), 8.05 (d, J = 7.1 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 55.5, 113.8, 119.30, 121.9, 125.0, 126.3, 126.9, 128.5, 129.3, 131.7, 132.1, 134.1, 137.5, 137.7, 147.6, 149.2, 155.5, 155.7, 163.9, 193.1; IR (KBr) υmax 2923, 1667, 1626, 1552, 1232, 1220, 831 cm-1; ESI-MS 491 [M+H]+; HRMS (ESI) calcd for C26H16N2O2SCl2 [M+H]+ 491.03823, found 491.03842.(

Derpharma-chemica-dichlorophenyl

Figure 29. 1H NMR of (Z)-(2-((2,4-dichlorophenyl)imino)-7-methoxy-2H-thiopyrano[2,3-b]quinolin-3-yl)(phenyl)methanone (3n).

Derpharma-chemica-thiopyrano

Figure 30. 13C NMR of (Z)-(2-((2,4-dichlorophenyl)imino)-7-methoxy-2H-thiopyrano[2,3-b]quinolin-3-yl)(phenyl)methanone (3n).

)

(Z)-(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b] quinolin-3-yl)(4-methoxyphenyl) methanone (3o)

Yellow solid; Yield: 84%; Rf (30% EtOAc/hexane) 0.47; m.p. 195-196 °C; 1H NMR (300 MHz, CDCl3) δ 3.88 (d, J = 5.4 Hz, 3H), 3.98 (s, 3H), 6.84 (d, J = 7.31 Hz, 1H), 6.97 (d, J = 9.1 Hz, 2H), 7.13 - 7.05 (m, 2H), 7.41 - 7.29 (m, 4H), 7.69 - 7.53 (m, 1H), 7.82 (d, J = 9.1 Hz, 1H), 8.05 – 7.96 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 55.5, 55.6, 105.1, 113.8, 113.9, 119.0, 122.1, 124.7, 125.0, 125.6, 127.4, 128.8, 129.3, 129.5, 132.1, 134.2, 136.2, 144.0, 149.3, 156.0,157.9, 163.9, 193.2; IR (KBr) υmax2931, 1601, 1546, 1255, 1218, 1029 cm-1; ESI-MS 453 [M+H]+; HRMS (ESI) calcd for C27H20N2O3S [M+H]+ 453.12674, found 453.12567. (Figure 31 and 32)

Derpharma-chemica-phenylimino

Figure 31. 1H NMR of (Z)-(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)(4-methoxyphenyl)methanone (3o).

Derpharma-chemica-quinolin

Figure 32. 13C NMR of (Z)-(7-methoxy-2-(phenylimino)-2H-thiopyrano[2,3-b]quinolin-3-yl)(4-methoxyphenyl)methanone (3o).

(4-Ethylphenyl)(1-phenyl-2-thioxo-1,2-dihydrobenzo[b][1,8]naphthyridin-3-yl) methanone (4a)

Brick red solid; Yield (10%); Rf (30% EtOAc/hexane) 0.47; m.p. 245-246oC; 1H NMR (300 MHz, CDCl3) δ 1.25 (t, J = 7.5 Hz, 3H), 2.74-2.67 (q, J = 7.5 Hz, 2H), 7.29 (d, J = 8.3 Hz, 3H), 7.32 (s, 1H), 7.57-7.50 (m, 2H), 7.62 (t, J= 8.3 Hz, 2H), 7.71 (t, J= 10.0 Hz, 1H), 7.77 (d, J= 10.0, 2H), 7.91 (t, J= 8.3 Hz, 3H), 8.49 (s 1H); 13C NMR (75 MHz, CDCl3) δ 15.0, 29.0, 117.7, 125.3, 126.3, 127.8, 128.2, 128.4, 128.8, 129.1, 129.6, 129.9, 131.9, 134.0, 137.1, 140.4, 142.2, 148.0, 149.9, 150.6, 186.4,192.4; IR (KBr) υmax 2926, 1660, 1610, 1287, 730 cm-1; ESI-MS 421[M+H]+; HRMS (ESI) calcd for C27H20ON2S [M+H]+ 421.13691, found 421.13553. (Figure 33 and 34)

Derpharma-chemica-dihydrobenzo

Figure 33. 1H NMR of (4-Ethylphenyl)(1-phenyl-2-thioxo-1,2-dihydrobenzo [b][1,8] naphthyridin-3- yl)methanone (4a).

Derpharma-chemica-naphthyridin

Figure 34. 13C NMR of (4-Ethylphenyl)(1-phenyl-2-thioxo-1,2-dihydro benzo [b] [1,8] naphthyridin-3- yl)methanone (4a).

Result and Discussion

In a typical reaction, 3-(4-ethylphenyl)-3-oxo-N-phenyl propanethioamide (1a) and 2-chloroquinoline-3-carbaldehyde (2a) were reacted in ethanol using DMAP (10 mol%) as catalyst under different set of conditions. Initially, the reaction was conducted at room temperature for 24 hours and found to be no reaction (Table 1, entry 2). However, the same reaction was conducted under reflux condition for 4 hours (Table 1, entry 3) resulted two isomers such as (Z)-(4-Ethyl phenyl)(2-(phenylimino)-2H-thiopyrano[2,3-b] quinolin-3-yl)methanone 3a (90%, S-cyclization product) and trace amount of (4-Ethylphenyl)(1-phenyl-2-thioxo-1,2-dihydrobenzo[b][1,8 naphthyridin-3-yl)methanone 4a (N-cyclization product). Encouraging by this result, we extensively screened the effect of solvents on the formation of products. The reaction is conducted in different solvents such as toluene, THF, DMF, H2O and Dioxane with DMAP (10 mol%) as a catalyst under reflux conditions and observed the less yields when compared to initial hit solvent ethanol (Table 1, entry 4-9). (Scheme 1).

Derpharma-chemica-Synthesis

Scheme 1: Synthesis of compound 3a and compound 4a

Table 1: Optimization studies for the synthesis of compound 3a and compound 4a.

S no Catalyst (mol%) Solvent Time(h) Temp(C) Yield(3a) Yield(4a)
1 EtOH 24 rt NR NR
2 DMAP(10) EtOH 24 rt NR NR
3 DMAP(10) EtOH 4 reflux 90 trace
4 DMAP(10) Toluene 4 reflux 85 trace
5 DMAP(10) THF 4 reflux 82 trace
6 DMAP(10) DMF 4 reflux 80 trace
7 DMAP(10) Dioxane 4 reflux 78 trace
8 DMAP(10) CH3CN 4 reflux 81 trace
9 DMAP(10) water 4 reflux NR NR
10 DMAP(20) EtOH 4 reflux 86 trace
11 DMAP(5) EtOH 4 reflux 70 trace
12 Piparazine(10) EtOH 4 reflux 72 10
13 DABCO(10) EtOH 4 reflux 65 8
14 Et3N(10) EtOH 4 reflux 78 8
15 ALCL3(10) EtOH 4 reflux NR NR
16 InCL3(10) EtOH 4 reflux NR NR
17 K2CO3(10) EtOH 4 reflux NR NR
18 KOH(10) EtOH 4 reflux NR NR
19 BF3ET2O(10) EtOH 4 reflux NR NR

To study the feasibility, we examined the reaction in ethanol with a different kind of catalysts such as piperazine, DABCO, pyrrolidine, triethylamine, Aluminium(III) chloride, Indium(III) chloride, potassium carbonate, potassium hydroxide, and Boron trifluoride diethyl etherate 10 mol% each under reflux conditions (Table 1, entry 12-19). In the case of piperazine, we found title compound 3a in 72% yield along with the compound dihydrobenzo[b][1,8] naphthyridin (4a) in 10% yield and both these structures are confirmed by a single X-ray crystallography technique. DMAP is the preferred catalyst in ethanol solvent facilitated a higher product yield (Table 1, entry 3). The detailed screening of solvents and catalysts are tabulated in Table 1.

By using the above-optimized conditions, we have synthesized several thiopyrano quinoline compounds and found that it is tolerated in different electron-withdrawing and releasing groups. Compound 1 having electron-donating groups (ethyl or methoxy) proceeded the reaction smoothly to afford the corresponding products 3a (92%), 3b (92%), 3j (87%), and 3o (84%) in excellent yields. The halogen group (fluorine and chlorine on aryl group R1) substituted β-aroyl-thioacetanilides have easily tolerated the reaction and furnished the corresponding products 3d, 3e, 3f, 3h, 3m and 3l respectively in excellent yields (81%, 83%, 80%, 89%, 92% and 95%). Further, we examined the para-methoxy and ortho, para-dichloro substituted β-aroyl-thioacetanilide (on aryl group R2) and observed the product 3k (79%) and 3n (75%) in good yields.

A plausible mechanism for the product formation is indicated in Scheme 3, the first step consists of DMAP catalyzed Knovenagel condensation between the quinoline aldehyde [2] and active methylene group of 3-oxo-N,3-diarylpropanethioamide [1] leading to the formation of intermediate [A] (Z)-2-benzoyl-3-(2-chloroquinolin-3-yl)-N-phenylprop-2-enethioamide next, the (DMAP) base abstract the proton from [A] generated anion on –NH- gives intermediate [B], which undergoes rapid keto-enol tautomerization forms intermediate [C] further chemo-selective intramolecular Scyclization to yielded the product 3 and a trace amount of N- cyclization to forms the product 4 outlined in Scheme 2.

Derpharma-chemica-thioacetanilides

Scheme 2: Scope of β-aroyl-thioacetanilides (1) and 2-chloro quinoline-3-carbaldehyde (2).

Derpharma-chemica-Mechanism

Scheme 3: Mechanism for the formation of compound 3 and 4.

The newly synthesized polysubstituted thiopyrano[2,3-b]quinolines (3a-3o) and benzo[b][1,8] naphthyridine derivative (4a) were thoroughly characterized by IR, HRMS, 1H- and 13C-NMR spectral data. The individual structures of (Z)-(4-Ethylphenyl)(2-(phenylimino)-2H-thiopyrano[2,3- b] quinolin-3-yl)methanone (3a) and (4-Ethylphenyl)(1-phenyl-2-thioxo-1,2-dihydrobenzo[b][1,8] naphthyridin-3-yl)methanone (4a) were further established by the X-ray diffraction analysis (Figure 35) of their single crystals obtained from ethanol.

Derpharma-chemica-crystallography

Figure 35. Representative X-ray crystallography structures of 3a and 4a. CCDC number of 3a is 1561445 and CCDC number of 4a is 1561446.

Conclusion

In summary, we have successfully developed a simple, efficient DMAP catalyzed cascade protocol for the synthesis of variously substituted functionalized thiopyrano [2,3-b]quinoline derivatives (3a-3o) accessible β-aroyl-acetanilides and 2-chloro quinoline-3-carbaldehydes , This protocol is effective along with well functional group tolerance which demonstrate its synthetic importance.

Acknowledgment

The authors acknowledge the financial support from the Council of Scientific and Industrial Research (CSIR-IICT), India.

rokettube brazzers

paper.io

agar io

wowcappadocia.com
cappadocia-hotels.com
balloon-rides.net

wormax io

Smok
Elektronik Sigara